We upgrade FRT from MARKET PERFORM to OUTPERFORM and raise our TP by 5% in conjunction with a 6% upward revision to our 2019F NPAT-MI as iPhone margins have recovered faster than we expected. However, we cut 2020F/2021F NPAT-MI by 3% as pharmacy GPM is trailing our previous forecasts. We expect the recovery in iPhone margins, a widening revenue contribution from high-margin accessories and shrinking net interest expenses to drive a 20% YoY